LGVN Longeveron

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.

Details for the Company’s corporate presentation:

  • Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ET
  • Longeveron presentation webcast link:

The webcast for this conference presentation may be accessed at the “” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit or follow Longeveron on , , and .

Investor and Media Contact:

Derek Cole

Investor Relations Advisory Solutions



EN
09/06/2025

Underlying

LGVNLongeveron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Longeveron

 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron Announces Up To $17.5 Million Public Offering

Longeveron Announces Up To $17.5 Million Public Offering $5.0 million upfront with up to an additional $12.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants MIAMI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced the pricing of a public offering of 5,882,354 of the Company’s Class A common stock (or pre-funded warrant...

10h / 6m 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® to Report Second Quarter 2025 Financial Results and Host C...

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025 MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will report second quarter 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference ...

August 5, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluri...

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease Longeveron has licensed issued US Patent 12,168,028 B2, entitled “Methods for obtaining cardiomyogenic precursor cells” from the University of MiamiNew patent protects a method to derive GHRH-Receptor+ cardiomyogenic cells from pluripotent stem cells (PSCs)New technology substantially advances Longeveron’s repertoire of stem cell therapy technologiesOpportunity to expand pipeline in cardiovascular, rare and pediatric disease areas MIAMI, July 21, 2025 (GLOBE NEWSWI...

July 21, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase...

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric cardiomyopathies affect at least 100,000 children worldwideEffective treatment options are limited, with nearly 40% of children with DCM requiring a heart transplant or dying within two years of diagnosis MIAMI, July...

July 8, 2025 1 EN
 PRESS RELEASE
Free
LGVN LONGEVERON

Longeveron® Appoints Than Powell as Chief Business Officer

Longeveron® Appoints Than Powell as Chief Business Officer Mr. Powell to oversee Longeveron’s partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company’s overall business strategy, Alzheimer’s disease program partnering efforts, and international strategy fo...

June 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch